Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Share:

An essential updated review of COVID-19 early-treatment best practices is now available. (abstract | PDF | HTML)

[This treatment protocol and others can also be found at https://c19protocols.com.]

This international collaboration — comprised of physicians, like lead author Peter McCullough, MD, courageously treating patients despite the prevalence of “therapeutic nihilism” among government agencies like the NIH and FDA  —  outlines the urgency of, “prompt early initiation of sequenced multidrug therapy (SMDT) … to stem the tide of hospitalizations and death.”

The authors write: 

The early stage of viral replication provides a therapeutic window of tremendous opportunity to potentially reduce the risk of more severe sequelae in high risk patients. Precious time is squandered with a ‘wait and see’ approach … resulting in unnecessary hospitalization, morbidity, and death. … In newly diagnosed, high-risk, symptomatic patients with COVID-19, SMDT has a reasonable chance of therapeutic gain with an acceptable benefit-to-risk profile.

Included in the paper is a “sequential multidrug treatment algorithm” and summaries of the rationale and evidence for each component.

The abstract, including a link to download the full PDF, is available at the following URL: https://rcm.imrpress.com/EN/Y2020/V21/I4/517

A version in HTML format at: https://rcm.imrpress.com/article/2020/2153-8174/RCM2020264.shtml

Or the PDF can be directly downloaded using the following link: https://rcm.imrpress.com/EN/article/downloadArticleFile.do?attachType=PDF&id=5065

Please share this new article with your colleagues, any contacts you have in the media, and with leaders in your community. 

To overcome the increasing censorship of lifesaving information, it is imperative that everyone pitch in to see that this manuscript is distributed as widely as possible.